EA201590115A8 - Внеклеточная днк в качестве терапевтической мишени для бесплодия у особи женского пола и диагностического маркера - Google Patents

Внеклеточная днк в качестве терапевтической мишени для бесплодия у особи женского пола и диагностического маркера

Info

Publication number
EA201590115A8
EA201590115A8 EA201590115A EA201590115A EA201590115A8 EA 201590115 A8 EA201590115 A8 EA 201590115A8 EA 201590115 A EA201590115 A EA 201590115A EA 201590115 A EA201590115 A EA 201590115A EA 201590115 A8 EA201590115 A8 EA 201590115A8
Authority
EA
Eurasian Patent Office
Prior art keywords
infertility
therapeutic target
diagnostic marker
extracellular dna
women
Prior art date
Application number
EA201590115A
Other languages
English (en)
Other versions
EA201590115A1 (ru
EA028855B1 (ru
Inventor
Андре Хазу
Original Assignee
Ферринг Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ферринг Б.В. filed Critical Ферринг Б.В.
Publication of EA201590115A1 publication Critical patent/EA201590115A1/ru
Publication of EA201590115A8 publication Critical patent/EA201590115A8/ru
Publication of EA028855B1 publication Critical patent/EA028855B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Настоящее изобретение имеет отношение к применению ДНКазы в лечении бесплодия у особи женского пола и к применению cfDNA в качестве маркера бесплодия у особи женского пола.
EA201590115A 2012-08-03 2013-08-01 Внеклеточная днк в качестве терапевтической мишени для лечения бесплодия у особи женского пола и диагностического маркера EA028855B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12179265 2012-08-03
EP13156626 2013-02-25
PCT/IB2013/056321 WO2014020564A1 (en) 2012-08-03 2013-08-01 Cell-free dna as a therapeutic target for female infertility and diagnostic marker

Publications (3)

Publication Number Publication Date
EA201590115A1 EA201590115A1 (ru) 2015-07-30
EA201590115A8 true EA201590115A8 (ru) 2016-04-29
EA028855B1 EA028855B1 (ru) 2018-01-31

Family

ID=49165809

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590115A EA028855B1 (ru) 2012-08-03 2013-08-01 Внеклеточная днк в качестве терапевтической мишени для лечения бесплодия у особи женского пола и диагностического маркера

Country Status (22)

Country Link
US (1) US9950040B2 (ru)
EP (1) EP2879696B1 (ru)
JP (1) JP6285436B2 (ru)
KR (1) KR102082735B1 (ru)
CN (1) CN104519906B (ru)
AU (1) AU2013298144B2 (ru)
CA (1) CA2880261C (ru)
DK (1) DK2879696T3 (ru)
EA (1) EA028855B1 (ru)
ES (1) ES2588387T3 (ru)
HK (1) HK1210592A1 (ru)
HR (1) HRP20161108T1 (ru)
HU (1) HUE030690T2 (ru)
IL (1) IL236924B (ru)
LT (1) LT2879696T (ru)
MX (1) MX359291B (ru)
NZ (1) NZ704039A (ru)
PL (1) PL2879696T3 (ru)
PT (1) PT2879696T (ru)
RS (1) RS55087B1 (ru)
SI (1) SI2879696T1 (ru)
WO (1) WO2014020564A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
EP1880733A4 (en) 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich METHOD FOR EXTENDING THE LIFE OF A HUMAN AND ANIMALS
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
AU2011358564B9 (en) 2011-02-09 2017-07-13 Natera, Inc Methods for non-invasive prenatal ploidy calling
US10617743B2 (en) * 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
WO2015197858A1 (en) * 2014-06-27 2015-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods employing circulating dna and mirna as biomarkers for female infertility
US10184150B2 (en) 2014-06-27 2019-01-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Free nucleic acids and miRNA as non-invasive method for determining embryo quality
KR101751962B1 (ko) 2015-04-30 2017-06-30 주식회사 넥스바이오 세포-유리형 dna의 위암 진단 용도
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
CN110945136A (zh) 2017-06-20 2020-03-31 威斯康星州立大学医学院 使用总无细胞dna评估移植并发症风险
CA3084620C (en) 2017-09-18 2024-06-18 Santersus Sa Method and device for purification of blood from circulating cell free dna
AU2019209770A1 (en) 2018-01-16 2020-09-03 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
CN110144345B (zh) * 2019-05-10 2022-07-15 上海交通大学 一种从卵泡液中提取cfDNA的方法
EP3760740A1 (fr) 2019-07-05 2021-01-06 Hazout, André Utilisation du niveau d'adn libre comme marqueur de l'endometriose
WO2021207244A1 (en) * 2020-04-06 2021-10-14 The Medical College Of Wisconsin, Inc. Methods for assessing the severity of, and for inhibiting, pro-inflammatory responses with total cell-free dna
EP4026557A1 (fr) * 2021-01-06 2022-07-13 Endolife Utilisation d'une désoxyribonucléase i dans le traitement de l'endométriose chez des patientes présentant une signature épigénétique de l'endométriose sur l'adn acellulaire
WO2023126672A1 (en) 2021-12-27 2023-07-06 Santersus Ag Method and device for removal of circulating cell free dna

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131108A2 (en) * 2006-05-03 2007-11-15 Tmi Laboratories International, Inc. Method to diagnose and increase fertility of mammalian semen using dnase as diagnostic marker and therapeutic agent
CN105664141A (zh) * 2006-10-18 2016-06-15 派利尼斯有限公司 脱氧核糖核酸酶在制备用于治疗男性低生育力的药物中的应用
EP1944611A1 (en) * 2007-01-11 2008-07-16 Université de la Méditerranée Biomarker for the medicine and the biology of the reproduction
US20150010527A1 (en) * 2012-02-01 2015-01-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy

Also Published As

Publication number Publication date
NZ704039A (en) 2018-04-27
EP2879696A1 (en) 2015-06-10
EA201590115A1 (ru) 2015-07-30
CA2880261C (en) 2021-02-02
JP6285436B2 (ja) 2018-02-28
CN104519906B (zh) 2016-10-05
AU2013298144B2 (en) 2018-03-08
HUE030690T2 (en) 2017-05-29
IL236924B (en) 2018-05-31
HRP20161108T1 (hr) 2016-11-04
LT2879696T (lt) 2016-09-26
ES2588387T3 (es) 2016-11-02
SI2879696T1 (sl) 2016-10-28
CA2880261A1 (en) 2014-02-06
KR20150036776A (ko) 2015-04-07
RS55087B1 (sr) 2016-12-30
US9950040B2 (en) 2018-04-24
EA028855B1 (ru) 2018-01-31
EP2879696B1 (en) 2016-06-08
AU2013298144A1 (en) 2015-02-19
MX359291B (es) 2018-09-24
CN104519906A (zh) 2015-04-15
US20150246103A1 (en) 2015-09-03
KR102082735B1 (ko) 2020-02-28
WO2014020564A1 (en) 2014-02-06
PT2879696T (pt) 2016-09-09
JP2015526079A (ja) 2015-09-10
DK2879696T3 (en) 2016-09-12
PL2879696T3 (pl) 2016-12-30
MX2015001538A (es) 2015-05-11
HK1210592A1 (zh) 2016-04-29

Similar Documents

Publication Publication Date Title
EA201590115A8 (ru) Внеклеточная днк в качестве терапевтической мишени для бесплодия у особи женского пола и диагностического маркера
PH12019502292A1 (en) Methods and compositions for treatment of a genetic condition
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
JO3357B1 (ar) مركبات إيميدازوبيروليدينون
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201790273A1 (ru) Флагеллиновые композиции и их применение
DOP2015000012A (es) Acidos 5-aminotetrahidroquinolin-2-carboxilicos novedosos y su uso
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
CL2014002846A1 (es) Usos terapéuticos de proteínas del factor de crecimiento del fibroblasto 21.
EA201500371A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
HK1215173A1 (zh) 治療金黃色葡萄球菌相關疾病的方法
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
EA201500370A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ
UY34843A (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
EA201590708A1 (ru) Модифицированные производные гиалуроновой кислоты и их применение
MX2016001686A (es) Composicion para el tratamiento contra el envejecimiento de la piel.
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης